Eric Schadt

This profile gathers the share dealings of Eric Schadt in GeneDx Holdings Corp., where the filings describe the role as chief executive. In total, 7 filings cover trades dated from 25 October 2021 to 20 May 2022.

The open-market side counts 1 purchase for €182k alongside 2 sales for €149k. Purchases outweigh sales by €33k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant and 3 option exercises. Since January 2022: 1 purchase and 2 sales on the market.

Most recently, on 24 May 2022, the filings show an open-market purchase worth €182k in GeneDx Holdings Corp. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.